EPIX — ESSA Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $76.79m
- -$43.76m
- 48
- 44
- 24
- 32
Annual cashflow statement for ESSA Pharma, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | C2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -23.4 | -36.8 | -35.1 | -26.6 | -28.5 |
| Depreciation | |||||
| Non-Cash Items | 7.59 | 9.33 | 7.76 | 4.34 | 6.15 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.24 | 1.95 | -0.78 | 2.34 | -0.419 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | -17 | -25.4 | -28 | -19.8 | -22.7 |
| Other Investing Cash Flow Items | -21.7 | -35 | -53.1 | -3.53 | 91.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -21.7 | -35 | -53.1 | -3.53 | 91.8 |
| Financing Cash Flow Items | -3.58 | -9.2 | -0.067 | -0.068 | 0.046 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 41.8 | 142 | 0.253 | -0.068 | 0.926 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3 | 81.5 | -80.7 | -23.4 | 70 |